DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymphoma (DLBCL) after receiving at least 2 lines of therapy, primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL) after receiving at least one line of therapy, mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy, and DLBCL transplant-ineligible after receiving at least one line of therapy.
DLBCL cohort (both cohorts)
DLBCL or associated subtype, defined by WHO 2016 classification
DLBCL not otherwise specified (NOS)
High-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
Primary CNS lymphoma (not applicable to CNS cohort)
Richter's transformed DLBCL arising from chronic lymphocytic leukemia (CLL) (not applicable to RT cohort)
Unable to give informed consent
Known history of infection with human immunodeficiency virus (HIV) or active hepatitis B (HBsAg positive). If there is a history of treated hepatitis B or hepatitis C, the viral load must be quantitative polymerase chain reaction (PCR) negative; antiviral prophylaxis is required if HBsAg negative and anti-HBc positive
Single group
zamtocabtagene autoleucel (MB-CART2019.1)
Biological/VaccineChimeric antigen receptor (CAR) T cell therapy
Cyclophosphamide
DrugLymphodepleting chemotherapy
Fludarabine
DrugLymphodepleting chemotherapy
Bendamustine
DrugLymphodepleting chemotherapy
Objective Response Rate
ORR
Complete Response Rate
CRR
Duration of Response
DOR
Overall Response Rate
ORR
Best Overall Response
BOR
Click on the lead sponsor to view all of their trials.
